Simon Baker

Simon Baker asked for insights into the market opportunity and size for RINVOQ in nonsegmental vitiligo, and about the pricing strategy for Elahir's UK launch, specifically if it signals a shift towards a U.S.-style gross-to-net market in Europe.

Answer

EVP and CCO Jeff Stewart estimated the next wave of RINVOQ indications (alopecia areata, vitiligo, HS, lupus) to have at least $2 billion in peak revenue potential, noting RINVOQ's potential as the first systemic treatment for vitiligo. He confirmed Elahir's UK list price is similar to the U.S., but acknowledged that European markets are HTA-driven, and net prices will be determined through evaluations like NICE.

Simon Baker asked about the market opportunity size for RINVOQ in nonsegmental vitiligo and inquired about ELAHERE's U.K. pricing strategy, specifically if it signals a shift towards a U.S.-style gross-to-net market in Europe.

Answer

Jeff Stewart, Executive Vice President, Chief Commercial Officer, estimated the combined peak revenue potential for RINVOQ's next wave of indications (alopecia areata, vitiligo, HS, lupus) to be at least $2 billion, noting vitiligo's segmentation. Regarding ELAHERE's U.K. pricing, he confirmed the list price is similar to the U.S. but acknowledged that net prices in HTA markets like the U.K. will be determined after NICE evaluation, and AbbVie desires reforms in European pricing systems.